Oocyte cryopreservation: is it time to remove its experimental label?
As more reproductive-age women survive cancer at the expense of gonadotoxic therapy, the need for viable fertility preservation options has become paramount. Embryo cryopreservation, often using donor sperm, has been the standard offered these women over the past 20 years. Preservation of unfertilized oocytes now represents an acceptable and often equally viable alternative, particularly for single women, due to technologic advances made in the past decade. Given such, oocyte cryopreservation's experimental designation and need for IRB approval should thus be revisited.
NYU Fertility Center, NYU School of Medicine, New York, NY 10016, USA. nnoyes01@gmail.com
Nicole
N
Noyes
Jeffrey
J
Boldt
Zsolt Peter
ZP
Nagy
D000970:Antineoplastic Agents / Q000009:adverse effects; D015925:Cryopreservation / Q000941:ethics / Q000379:methods; D019924:Embryo Disposition; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D054315:Oocyte Retrieval / Q000331:legislation & jurisprudence; D009865:Oocytes; D011247:Pregnancy; D011256:Pregnancy Outcome; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced; D027724:Reproductive Techniques, Assisted / Q000941:ethics / Q000331:legislation & jurisprudence; D020554:Sperm Injections, Intracytoplasmic; D017741:Survivors; D035703:Therapies, Investigational
D000970:Antineoplastic Agents